Trial Profile
A Real World Study of Ibrutinib in Swedish Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia Treated in a Compassionate Use Program (CUP)
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 24 Jul 2018
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Expanded access; Therapeutic Use
- 24 Jul 2018 New trial record
- 17 Jun 2018 Results of long-term follow-up (30 months) and in-depth analyses of relapsed/refractory chronic lymphocytic leukemia patients treated with Ibrutinib in a compassionate use program (CUP) along with results of impact analysis of inclusion/exclusion criteria obtained from RESONATE trial on the study outcomes, presented at the 23rd Congress of the European Haematology Association.